Cargando…

Clinical Outcomes Based on Measurable Residual Disease Status in Patients with Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis

Measurable residual disease (MRD) response during acute myeloid leukemia (AML) treatment is a gold standard for determining treatment strategy, especially in core-binding factor (CBL) AML. The aim of this study was to critically review the literature on MRD status in the CBF-AML to determine the ove...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rotchanapanya, Wannaphorn, Hokland, Peter, Tunsing, Pattaraporn, Owattanapanich, Weerapat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711894/ https://www.ncbi.nlm.nih.gov/pubmed/33256157 http://dx.doi.org/10.3390/jpm10040250

Ejemplares similares

Efficacy of Targeted Immunotherapy as Induction or Salvage Therapy in Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis
por: Ponvilawan, Ben, et al.
Publicado: (2021)

Maintenance With Hypomethylating Agents After Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis
por: Kungwankiattichai, Smith, et al.
Publicado: (2022)

Comparison of the Long-Term Remission of Rituximab and Conventional Treatment for Acquired Thrombotic Thrombocytopenic Purpura: A Systematic Review and Meta-Analysis
por: Owattanapanich, Weerapat, et al.
Publicado: (2019)

Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis
por: Rungjirajittranon, Tarinee, et al.
Publicado: (2022)

FLAMSA-RIC for Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis
por: Owattanapanich, Weerapat, et al.
Publicado: (2019)

Comparative Efficacy and Clinical Outcomes of Haploidentical Stem Cell Transplantation to Other Stem Sources for Treatment in Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients: A Systematic Review and Meta-Analysis
por: Kunacheewa, Chutima, et al.
Publicado: (2020)

Efficacy and the Adverse Effects of Oral Versus Intravenous Arsenic for Acute Promyelocytic Leukemia: A Meta-Analysis of Randomized-Controlled Studies
por: Sasijareonrat, Natthaporn, et al.
Publicado: (2020)

Leukemic arthritis and severe hypercalcemia in a man with chronic myeloid leukemia: a case report and review of the literature
por: Rujirachun, Pongprueth, et al.
Publicado: (2018)

RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia
por: Kim, TaeHyung, et al.
Publicado: (2020)

Precursor B‐cell acute lymphoblastic leukaemia—a global view
por: Biondi, Andrea, et al.
Publicado: (2021)

Is stem cell transplantation still needed for adult Philadelphia chromosome-positive acute lymphoblastic leukemia receiving tyrosine kinase inhibitors therapy?: A systematic review and meta-analysis
por: Ponvilawan, Ben, et al.
Publicado: (2021)

Efficacy of local tranexamic acid treatment for prevention of bleeding after dental procedures: A systematic review and meta-analysis
por: Owattanapanich, Duangrat, et al.
Publicado: (2019)

A 34-Year-Old Thai Man Presenting with Pulmonary Stenosis and Heart Failure 24 Years After Surgical Correction with the Rastelli Procedure for Congenital Dextro-Transposition of the Great Artery, Ventricular Septal Defect, and Pulmonary Atresia
por: Pongbangli, Natnicha, et al.
Publicado: (2022)

Simplified predictive scores for thrombosis and bleeding complications in newly diagnosed acute leukemia patients
por: Owattanapanich, Weerapat, et al.
Publicado: (2023)

Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome—excess blasts detected by next-generation sequencing technique
por: Owattanapanich, Weerapat, et al.
Publicado: (2021)

Prevention of High-Dose Cytosine Arabinoside-Induced Acute Pericarditis with Preemptive Dexamethasone Administration: A Case Report and Literature Review
por: Owattanapanich, Weerapat, et al.
Publicado: (2018)

Therapy-related core binding factor acute myeloid leukemia
por: George, Binsah, et al.
Publicado: (2023)

Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia
por: Roloff, Gregory W., et al.
Publicado: (2017)

Measurable Residual Disease in High-Risk Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2022)

Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia
por: Azenkot, Tali, et al.
Publicado: (2022)

Improved detection of measurable residual disease in acute myeloid leukemia
por: Zhang, Xuan, et al.
Publicado: (2023)

Stem Cell Modeling of Core Binding Factor Acute Myeloid Leukemia
por: Mosna, Federico, et al.
Publicado: (2016)

SNP-array lesions in core binding factor acute myeloid leukemia
por: Duployez, Nicolas, et al.
Publicado: (2018)

Detection of KIT mutations in core binding factor acute myeloid leukemia
por: Badr, Passant, et al.
Publicado: (2018)

Measurable residual disease monitoring provides insufficient lead-time to prevent morphological relapse in the majority of patients with core-binding factor acute myeloid leukemia
por: Puckrin, Robert, et al.
Publicado: (2020)

Direct oral anticoagulants versus low-molecular-weight heparins for the treatment of acute venous thromboembolism in patients with gastrointestinal cancer: a systematic review and meta-analysis
por: Rungjirajittranon, Tarinee, et al.
Publicado: (2022)

Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia
por: Yoest, Jennifer M., et al.
Publicado: (2020)

Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia
por: Aitken, Marisa J. L., et al.
Publicado: (2021)

Delving the depths of measurable residual disease negativity in acute myeloid leukemia
por: Freeman, Sylvie D.
Publicado: (2022)

The present and future of measurable residual disease testing in acute myeloid leukemia
por: Blachly, James S., et al.
Publicado: (2022)

Role of Measurable Residual Disease in Older Adult Acute Myeloid Leukemia
por: Li, Xueyao, et al.
Publicado: (2023)

Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia
por: Senapati, Jayastu, et al.
Publicado: (2022)

Measurable residual disease in chronic myeloid leukemia
por: Branford, Susan, et al.
Publicado: (2022)

A serious thrombotic event in a patient with immune thrombocytopenia requiring intravenous immunoglobulin: a case report
por: Rungjirajittranon, Tarinee, et al.
Publicado: (2019)

Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis
por: Treewaree, Sukrit, et al.
Publicado: (2023)

Targeted RNA-sequencing for the quantification of measurable residual disease in acute myeloid leukemia
por: Dillon, Laura W., et al.
Publicado: (2019)

Investigation of measurable residual disease in acute myeloid leukemia by DNA methylation patterns
por: Božić, Tanja, et al.
Publicado: (2021)

Acute Myeloid Leukemia Stem Cells in Minimal/Measurable Residual Disease Detection
por: Srinivasan Rajsri, Kritika, et al.
Publicado: (2023)

Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia
por: Gui, Gege, et al.
Publicado: (2023)

Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia
por: Gottardi, Michele, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gsou2nv4lv1pl43vd8j2r4t1m6